Trial Profile
Phase 2a Single-Dose, Randomized, Double Blind, Multi-Center, Parallel-Group, Placebo-Controlled Proof of Concept Study to Assess the Efficacy, Safety, Tolerability, and Population Pharmacokinetics of AIN457 in Patients With Stable Plaque-type Psoriasis
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Mar 2017
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Plaque psoriasis
- Focus Proof of concept; Therapeutic Use
- Sponsors Novartis
- 08 Mar 2017 Data from this and other trials (n=1233) was used in population pharmacokinetic modelling to characterize pharmacokinetic of secukinumab in patients with psoriasis; outcomes published in the Journal of Clinical Pharmacology
- 28 Nov 2014 New trial record